CyclopharmASX:CYC 46 OCF Yield % is -27.49 as of Jun. 28, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 117 Medical Distribution companies, Cyclopharm ranks worse than 93.16% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cyclopharm OCF Yield % Related Terms
Cyclopharm OCF Yield % Historical Data
* Premium members only.
The historical data trend for Cyclopharm's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cyclopharm's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm OCF Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Cyclopharm's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a OCF Yield % of -27.49 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #109 out of 117 companies in the Medical Distribution industry, placing it in the top 93.2%.
Is Cyclopharm's OCF Yield % too high?
Cyclopharm's current OCF Yield % is -27.49. Based on the distribution chart, Cyclopharm ranks #109 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's OCF Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #109 out of 117 companies for OCF Yield %. This places Cyclopharm in the lower half of its industry. The industry median OCF Yield % is 5.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Distribution company?
The median OCF Yield % among Medical Distribution companies is 5.97, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median OCF Yield % is 5.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current OCF Yield % is -27.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current OCF Yield % is -27.49. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current OCF Yield % is -27.49 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
OCF Yield %: -27.49
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
